ZNF705A
Zinc finger protein 705A
Also known as: FLJ16353, Z705A_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q6ZN79
- Gene
- ZNF705A
- Ensembl
- ENSG00000196946
- Chromosome
- 12
- Canonical length
- 300 aa
- Protein class
- Predicted intracellular proteins, Transcription factors
OverviewNCBI Gene
Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II transcription regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be located in chromatin. Predicted to be active in nucleus. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
300 residues, UniProt reviewed canonical sequence.
>Q6ZN79|ZNF705A
1 MHSLKKVTFE DVAIDFTQEE WAMMDTSKRK LYRDVMLENI SHLVSLGYQI SKSYIILQLE
61 QGKELWREGR EFLQDQNPDR ESALKKKHMI SMHPITRKDA STSMTMENSL ILEDPFECND
121 SGEDCTHSST ITQRLLTHSG KKPYVSKQCG KSLRNLFSPK PHKQIHTKGK SYQCNLCEKA
181 YTNCFRLRRH KMTHTGERPY ACHLCGKAFT QCSHLRRHEK THTGERPYKC HQCGKAFIQS
241 FNLRRHERTH LGKKCYECDK SGKAFSQSSG FRGNKIIHTG EKPHACLLCG KAFSLSSDLRLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ZNF705A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.46
- Highest tissue expression
- 2.2 nTPM
Expression across tissuesHPA
Tissue
- epididymis: 2.2 nTPM
- testis: 1.6 nTPM
- cerebral cortex: 1.3 nTPM
- endometrium: 1.1 nTPM
- thyroid gland: 1.1 nTPM
- ovary: 1 nTPM
Single-cell type
- early spermatids: 6 nCPM
- late spermatids: 3.6 nCPM
- late primary spermatocytes: 2.3 nCPM
- neutrophils: 0.5 nCPM
- podocytes: 0.3 nCPM
- epididymal principal cells: 0.2 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebral cortex: 3.8 nTPM
- hypothalamus: 3.4 nTPM
- basal ganglia: 3.3 nTPM
- amygdala: 3 nTPM
- hippocampal formation: 3 nTPM
- medulla oblongata: 3 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.7
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.39
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- DNA-binding transcription factor activity, RNA polymerase II-specific
- RNA polymerase II transcription regulatory region sequence-specific DNA binding
- zinc ion binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ZNF705A as an antibody target. Whether an autoantibody or antibody against ZNF705A could matter depends on whether native ZNF705A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ZNF705A is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label ZNF705A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...